Xenomics developed a test for the detection of NPM
gene mutations, a recently discovered genetic marker for acute myeloid leukemia (AML). Xenomics already holds the exclusive license for the use of that marker.
“The NPM genetic marker is critically important to physicians because it can provide a diagnostic tool to identify an especially aggressive form of AML much more rapidly and effectively than conventional techniques,” explains David Tomei, Ph.D., CEO and co-founder. “This test developed by Xenomics is capable of detecting all known NPM mutations in DNA from bone marrow or blood cells of AML patients in one reaction with high sensitivity and specificity.
“We are now preparing to move this test into the clinical setting,” adds Dr. Tomei.